查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2112457

細胞收集系統：市場洞察、競爭格局和市場預測 - 2034 年

Cell Harvesting Systems - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

概述：

  • 2025年全球細胞收集系統市場價值為35.9億美元，預計2034年將達到91.4億美元。
  • 在 2026 年至 2034 年的預測期內，該市場預計將以 10.95% 的複合年成長率成長，這主要得益於生物製藥生產規模的擴大、細胞和基因療法以及再生醫學的快速發展、向自動化和閉迴路一次性加工的轉變以及對細胞研究投資的增加。
  • 按類型分類，預計到 2025 年，自動化細胞收集系統細分市場將佔 59% 的市場佔有率，從而推動細胞收集系統市場的發展。
  • 按應用領域分類，預計生物製藥領域將在細胞收集系統市場中佔主導地位，到 2025 年將佔市場佔有率的 52%。
  • 按最終用戶分類，預計生物技術和生物製藥公司將在細胞收集系統市場中佔主導地位，到 2025 年將佔市場佔有率的 57%。
  • 截至 2025 年，北美在細胞收集系統市場中佔最大佔有率，為 33%，但預計到 2034 年，亞太地區將實現最快成長。

細胞回收是指在細胞培養後，從培養基或過濾液中分離並回收活細胞的過程。它是細胞培養和生物加工過程中至關重要的一步，能夠提供生物製藥生產、幹細胞治療、癌症研究和疫苗開發所需的活性細胞。回收過程包括從培養基中回收目標細胞和分泌物，同時移除用過的培養基、細胞殘留物和其他雜質。該過程必須在維持細胞活性的前提下進行，因為受損或受污染的細胞無法用於後續的下游治療或生產過程。市場根據回收方法的自動化程度、回收細胞的應用以及執行回收的機構進行細分。按類型分類，細胞回收系統可分為手動系統（研究人員進行離心和過濾，操作簡單且成本低廉，但勞動強度大，結果易受干擾）和自動化細胞回收系統（包括機器人系統、自動離心機和微流體裝置，可提高產量、可重複性和製程安全性，並實現封閉式和可擴展的製程流程）。按應用領域分類，範圍涵蓋生物製藥生產、幹細胞研究及其他用途。依最終用戶分類，目標客戶為生技公司、生物製藥公司和研究機構。本次評估採用系統性評估方法，不僅涵蓋回收設備，還包括回收過程中使用的耗材、過濾器和試劑等一次性耗材。目前市場特徵是自動化、一次性使用和閉迴路處理、向深度過濾和切向流過濾的轉變，以及細胞和基因治療的快速發展。

細胞收集系統市場的主要市場促進因素

  • 隨著生物製藥生產規模的不斷擴大，細胞收穫對於疫苗、重組蛋白和治療性抗體的生產至關重要，生物製造領域不斷成長的投資推動了對自動化和擴充性收集系統日益成長的需求。
  • 細胞和基因療法以及再生醫學，包括嵌合體抗原受體 T 細胞療法和幹細胞療法，正在迅速發展，需要無菌、可複製且在符合 GMP 標準的條件下收集的活性細胞。
  • 與人工離心和過濾相比，自動化、封閉式、一次性製程正在逐漸興起，這些製程可以降低污染風險、節省勞力，並提高產量和可重複性。
  • 隨著人們對個人化醫療的需求不斷成長，以及慢性病、危及生命的疾病和自體免疫疾病的發生率不斷上升，對新型細胞療法和臨床研究的投資也不斷增加。
  • 一次性技術（包括一次性離心機、深度過濾和切向流過濾）被廣泛採用的趨勢日益明顯，這些技術被整合到閉迴路採樣工作流程中。
  • 美國食品藥物管理局(FDA) 的先進製造技術認定計畫等監管支持，正加速檢驗自動化技術的採用。
  • 即時製程監控、人工智慧以及微流體和實驗室晶片系統的整合最佳化了收穫產量、活力和擴充性。

推動細胞收集系統市場成長的因素

市場促進因素

擴大生物製藥生產規模

細胞收集系統市場的主要驅動力是生物製藥生產的持續規模化。這是因為在所有細胞衍生生物製藥的生產過程中，收穫過程都是不可避免的重複性操作，而所需的收穫能力規模與生物製藥的產量成正比成長。高效的細胞收穫對於疫苗、重組蛋白和治療性單株抗體等生物製藥的生產至關重要。這些產品均在培養細胞中生產，需要對產品或細胞本身進行分離和回收。生物製造領域投資的增加以及全球對生物製藥日益成長的需求，正在推動生物製藥行業向自動化和擴充性的收集系統轉型。生物製藥產量與收穫需求的關係是機械性的，而非任意的。因為從臨床規模到商業化生產，每個生產批次都需要經過收穫和澄清過程，這不僅消耗收穫設備的處理能力，還會消耗一次性過濾器、深度過濾材料和相關耗材。隨著生物製藥研發管線的擴展，生物相似藥的應用範圍不斷擴大，全球產能也不斷提升以滿足需求，收穫製程的規模也隨之相應擴大。此外，現代生物反應器中細胞密度的增加加劇了澄清的難度，提高了每個批次所需收穫技術的價值。生物製藥是製藥業成長最快、價值最高的領域，由於每個生產單位都需要收穫，因此這一因素為市場成長奠定了最堅實的基礎。

細胞和基因療法以及再生醫學的擴展

細胞和基因療法以及再生醫學的快速發展是細胞採集系統市場強勁且獨特的驅動力。這是因為這些療法本身就包含活細胞，其採集條件遠比傳統生物製造更嚴格。嵌合體抗原受體T細胞療法、幹細胞療法和其他先進的細胞療法要求在無菌、可重複且符合GMP規範的條件下採集活細胞，並儘可能減少細胞損傷。這是因為採集的細胞本身就是治療產品，而非中間體，任何細胞活力的降低或污染的引入都會直接影響患者的治療效果。該領域的成長顯著，這得益於核准的細胞和基因療法數量的增加、臨床研發管線的不斷擴展以及對誘導性富潛能幹細胞系、3D類器官模型和基因編輯療法的投資。正因如此，幹細胞研究始終是細胞採集系統應用領域中成長最快的領域。自體療法目前已成為臨床實踐的主流，由於每批樣本都對應一位患者，因此對樣本採集的要求尤其嚴格。無菌性和按時完成採集是必要條件，這就要求採用密封和自動化採集方式。另一方面，隨著異體療法的出現，對樣本採集量的要求也隨之大規模。在細胞和基因治療中，樣本採集過程已從單純的生產步驟轉變為治療本身的重要組成部分，因此對高品質和嚴格控制的採集技術提出了更高的要求。

市場限制因素

儘管細胞收集系統市場擁有強勁且結構性支撐的需求基礎，但仍面臨許多重大限制因素。其中最主要的限制因素是自動化閉迴路回收系統的高昂初始投資成本。這筆成本可能相當可觀，阻礙了小規模實驗室、預算緊張的學術和研究機構以及對成本敏感的市場採用該系統。在這些市場中，儘管存在局限性，手動離心和過濾仍然是主流方法。手動方法所需的初始投資極少，並且允許研究人員在需要頻繁更改的實驗中直接操控系統。第二個限制因素是自動化系統的技術複雜性以及將其整合到現有生物製程和細胞治療工作流程中的挑戰。這是因為回收系統需要與上游培養和下游純化製程相連接，而必要的整合、驗證和製程開發會帶來成本高昂、耗時且專業化的負擔，這對小規模的機構而言尤其重要。第三個也是根本性的限制因素是難以在維持細胞活性的同時回收細胞。為了使下游製程中使用的細胞具有活性，必須在盡可能減少損傷的情況下回收細胞。然而，回收過程中固有的剪切力、溫度波動和處理時間可能會損傷被回收的細胞。對於脆弱的幹細胞和用於先進療法的原代培養細胞而言，這項挑戰尤其嚴峻。其他限制因素包括嚴格的法規和GMP要求，這些要求規範了用於臨床的細胞處理流程。這些因素增加了回收系統認證和運作的成本和複雜性。此外，能夠操作和驗證先進系統的熟練生物程序和細胞治療人員也十分短缺，而且在早期研發和低通量服務環境中，由於簡單性和低成本仍然具有優勢，勞動密集型的手工操作流程仍然存在。這些成本、技術、生物學和監管因素共同作用，使得細胞回收產業雖然發展強勁，但也面臨許多限制因素。

目錄

第1章：細胞收集系統市場：簡介

  • 調查範圍
  • 市場區隔
  • 市場概覽

第2章：細胞收集系統市場：摘要整理

  • 主要亮點和市場概覽

第3章：細胞收集系統市場：關鍵因素分析

  • 市場促進因素
    • 擴大生物製藥生產規模
    • 細胞和基因療法以及再生醫學的擴展
    • 向自動化和密封加工過渡
    • 一次性使用和過濾技術
  • 市場限制因素
    • 自動化系統的高資本投資成本
    • 技術複雜性與整合挑戰
    • 維持和調控細胞活力的複雜性
  • 市場機遇
    • 自動化密封細胞治療處理
    • 微流體技術、監測與新興市場

第4章：人工智慧、地緣政治、貿易與經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：波特五力分析

第7章 細胞收集系統市場：評估

  • 按類型
    • 手動細胞採集裝置
    • 自動化細胞收集裝置
  • 用途別
    • 生物製藥
    • 幹細胞研究
    • 其他用途
  • 最終用戶
    • 生物技術和生物製藥公司
    • 研究機構
    • 其他最終用戶
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：細胞收集系統市場：競爭格局

  • 競爭分析
  • 企業市場占有率分析（加值服務）

第9章 細胞收集系統市場：新創企業資金籌措與投資趨勢

第10章：細胞收集系統市場：公司概況與產品概況

  • Thermo Fisher Scientific Inc.
  • Danaher Corporation（Cytiva）
  • Sartorius AG
  • Merck KGaA
  • Terumo BCT（Terumo Corporation）
  • Lonza Group AG
  • Miltenyi Biotec BV & Co. KG
  • STEMCELL Technologies Inc.
  • Corning Incorporated
  • Revvity Inc.

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0830

Cell Harvesting Systems Market Summary

Overview:

  • The global cell harvesting systems market was valued at USD 3.59 billion in 2025 and is projected to reach USD 9.14 billion by 2034.
  • The market is expected to expand at a CAGR of 10.95% during the forecast period 2026-2034, supported by the scale-up of biologics manufacturing, the rapid expansion of cell and gene therapy and regenerative medicine, the shift toward automated and closed single-use processing, and rising investment in cell-based research.
  • By type, the automated cell harvesters segment dominated the cell harvesting systems market with a 59% share in 2025.
  • By application, the biopharmaceutical segment dominated the cell harvesting systems market with a 52% share in 2025.
  • By end-user, the biotechnology and biopharmaceutical companies segment dominated the cell harvesting systems market with a 57% share in 2025.
  • North America accounted for the largest share of the cell harvesting systems market at 33% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Cell harvesting is the process of separating and collecting live cells from a growth medium or culture after cell culture, and it is an essential procedure in cell culture and bioprocessing that supplies the viable cells required for biopharmaceutical production, stem cell therapy, cancer research, and vaccine development. The harvest step recovers the target cells or the secreted product from the culture while removing spent medium, cell debris, and other contaminants, and it must do so while preserving cell viability, since damaged or contaminated cells are unusable in the downstream therapy or manufacturing process that follows. The market is organized by the degree of automation of the harvesting method, the application for which the cells are harvested, and the organization that performs the harvest. By type, it divides between manual cell harvesters, which rely upon centrifugation and filtration performed by a researcher and are simple and inexpensive but labor-intensive and variable, and automated cell harvesters, which include robotic systems, automated centrifuges, and microfluidic devices that enhance yield, reproducibility, and process safety while enabling closed and scalable processing. By application, it spans biopharmaceutical production, stem cell research, and other applications, and by end-user it spans biotechnology and biopharmaceutical companies, research institutes, and others. This assessment adopts a systems scope that encompasses the harvesting instruments together with the single-use consumables, filters, and reagents consumed in the harvest step. The contemporary market is defined by the movement toward automation, single-use and closed processing, depth filtration and tangential flow filtration, and the rapid growth of cell and gene therapy.

Cell Harvesting Systems Market Key Growth Drivers

  • The continued scale-up of biologics manufacturing, since the harvesting of cells is essential to the production of vaccines, recombinant proteins, and therapeutic antibodies, and rising biomanufacturing investment increases demand for automated and scalable harvesting systems.
  • The rapid expansion of cell and gene therapy and regenerative medicine, including chimeric antigen receptor T-cell therapy and stem cell therapy, which require viable cells harvested under sterile, reproducible, and GMP-compliant conditions.
  • The shift toward automated and closed single-use processing, which reduces contamination risk, cuts labor, and improves yield and reproducibility relative to manual centrifugation and filtration.
  • Growing demand for personalized medicine and the rising incidence of chronic, life-threatening, and autoimmune diseases, which have propelled investment in novel cell therapies and clinical research.
  • The widespread adoption of single-use technologies, including single-use centrifuges, depth filtration, and tangential flow filtration integrated into closed harvesting workflows.
  • Regulatory support for advanced manufacturing, including the United States Food and Drug Administration Advanced Manufacturing Technologies Designation Program, which incentivizes the deployment of self-validating automation.
  • The integration of real-time process monitoring, artificial intelligence, and microfluidic and lab-on-a-chip systems that optimize harvest yield, viability, and scalability.

Key Companies in Cell Harvesting Systems Market

The leading participants in the cell harvesting systems market include the following:

  • Thermo Fisher Scientific Inc.
  • Danaher Corporation (Cytiva)
  • Sartorius AG
  • Merck KGaA
  • Terumo BCT (Terumo Corporation)
  • Lonza Group AG
  • Miltenyi Biotec B.V. & Co. KG
  • STEMCELL Technologies Inc.
  • Corning Incorporated
  • Revvity Inc.

Factors Contributing to the Growth of the Cell Harvesting Systems Market

Market Drivers

Scale-Up of Biologics Manufacturing

The foundational driver of the cell harvesting systems market is the continued scale-up of biologics manufacturing, since the harvest step is an unavoidable and recurring operation in the production of every cell-derived biologic, and the volume of harvesting capacity required rises directly with biomanufacturing output. Effective harvesting of cells is necessary for the production of biologics including vaccines, recombinant proteins, and therapeutic monoclonal antibodies, each of which is produced in cultured cells from which the product or the cells themselves must be separated and recovered, and the increasing investment in biomanufacturing and the growing global demand for biologics have propelled the biopharmaceutical application toward automated and scalable harvesting systems. The relationship between biologics output and harvesting demand is mechanical rather than discretionary, because every production batch, from clinical-scale through commercial manufacturing, passes through a harvest and clarification step that consumes both the harvesting instrument capacity and the single-use filters, depth filtration media, and consumables associated with it. As the biologics pipeline expands, as biosimilars broaden the manufactured pool, and as manufacturing capacity is added worldwide to meet demand, the harvest step scales in proportion, and the shift toward higher cell densities in modern bioreactors intensifies the clarification challenge and raises the value of the harvesting technology required per batch. Because biologics represent the fastest-growing and highest-value segment of the pharmaceutical industry, and because each unit of output requires harvesting, this driver provides the most durable foundation for market growth.

Expansion of Cell and Gene Therapy and Regenerative Medicine

The rapid expansion of cell and gene therapy and regenerative medicine is a powerful and distinctive driver of the cell harvesting systems market, because these therapies are themselves composed of living cells that must be harvested under conditions far more demanding than those of conventional biomanufacturing. Chimeric antigen receptor T-cell therapy, stem cell therapy, and other advanced cell therapies require viable cells to be harvested with minimal damage and under sterile, reproducible, and GMP-compliant conditions, since the harvested cells are not an intermediate but the therapeutic product itself, and any loss of viability or introduction of contamination directly compromises a treatment intended for a patient. The growth of this field has been extraordinary, driven by the accumulating number of approved cell and gene therapies, the expanding clinical pipeline, and the investment in induced pluripotent stem cell lines, three-dimensional organoid models, and gene-edited therapeutics, and stem cell research is consistently identified as the fastest-growing application of cell harvesting systems for precisely this reason. The autologous therapies that dominate current practice impose particularly stringent requirements, since each batch corresponds to a single patient and must meet sterility and timeline targets that reward closed and automated harvesting, while the emergence of allogeneic therapies scales the harvesting requirement toward larger volumes. Because cell and gene therapy converts the harvest step from a manufacturing operation into a component of the therapy itself, it drives demand for the highest-value and most tightly controlled harvesting technology.

Market Restraints

Despite a strong and structurally supported demand base, the cell harvesting systems market faces several material constraints. The most significant is the high capital cost of automated and closed harvesting systems, which can be substantial and which constrains adoption in smaller laboratories, in academic and research settings with limited budgets, and in cost-sensitive markets, where manual centrifugation and filtration consequently persist despite their limitations, since manual methods are simple to perform with minimal initial investment and can be directly handled by researchers for experiments involving frequent modification. A second constraint is the technical complexity of automated systems and the challenge of integrating them into existing bioprocessing and cell therapy workflows, since a harvesting system must connect to the upstream culture and downstream purification steps surrounding it, and the integration, validation, and process development required impose cost, time, and expertise burdens that weigh most heavily upon smaller organizations. A third and fundamental constraint is the difficulty of harvesting cells while preserving viability, since viable cells must be harvested with minimal damage if they are to be used in downstream applications, and the shear forces, temperature changes, and processing time inherent in harvesting can compromise the very cells the process is intended to recover, a challenge that is most acute for the fragile stem and primary cells used in advanced therapies. Additional constraints include the stringent regulatory and GMP requirements governing cell processing for clinical use, which raise the cost and complexity of qualifying and operating harvesting systems; the shortage of skilled bioprocessing and cell therapy personnel able to operate and validate advanced systems; and the persistence of labor-intensive manual methods in early-stage development and low-throughput service settings where their simplicity and low cost remain advantageous. Together these cost, technical, biological, and regulatory factors ensure that growth, while robust, proceeds against genuine constraint.

Cell Harvesting Systems Market Segment Analysis

The global cell harvesting systems market is segmented by type (manual cell harvesters and automated cell harvesters); by application (biopharmaceutical, stem cell research, and other applications); by end-user (biotechnology and biopharmaceutical companies, research institutes, and others); and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Type

Dominant Subsegment: Automated Cell Harvesters.

The automated cell harvesters segment accounted for a 59% share of the cell harvesting systems market in 2025. Automated cell harvesters dominate the type structure because they hold the promising potential of improving yield, reproducibility, and process safety that manual methods cannot deliver, and because the manufacturing and clinical applications that account for the majority of harvesting demand require exactly these attributes. Automated harvesting devices mitigate contamination chances, facilitate closed processing, and can be connected to upstream and downstream bioprocessing systems, which makes them the technology of choice for the biopharmaceutical production and cell therapy manufacturing that dominate the market, where sterility, batch-to-batch consistency, and integration into a connected process train are decisive. The category encompasses robotic cell harvesting systems systems, automated centrifuges, and microfluidic harvesting devices, and its leadership is reinforced by the widespread adoption of advanced, closed, and automated harvesters that reduce labor requirements and improve batch consistency, an advantage of growing weight given the shortage of skilled bioprocessing personnel. Manual cell harvesters constitute the second category, relying upon centrifugation and filtration performed by a researcher, and they retain importance for early-stage development and low-throughput service because they are simple to perform with minimal initial investment, can be directly handled by researchers, and suit experiments involving frequent modification, though they are labor-intensive, susceptible to variability, and far less amenable to large-scale manufacturing. Automated cell harvesters are expected to retain their leading share and to grow throughout the forecast period as automation deepens across the field.

By Application

Dominant Subsegment: Biopharmaceutical.

The biopharmaceutical segment accounted for a 52% share of the cell harvesting systems market in 2025. The biopharmaceutical application dominates the application structure, owing to the extensive utilization of cell-based systems in the drug manufacturing process, since effective harvesting of cells is necessary for the production of biologics including vaccines, recombinant proteins, and therapeutic antibodies. The increasing investment in biomanufacturing and the growing demand for biologics have further propelled this segment toward automated and scalable harvesting systems, and the scale of the underlying activity sustains its position, since every production batch of a cell-derived biologic, from clinical through commercial manufacturing, passes through a harvest and clarification step that consumes both harvesting instrument capacity and the single-use filters and consumables associated with it. The commercial biologics pool, supported by an increasing number of on-market therapies and by the expansion of biosimilars, anchors the segment, and the shift toward higher cell densities in modern bioreactors intensifies the clarification challenge and raises the value of the harvesting technology required per batch. Stem cell research constitutes the second application and the fastest-growing, driven by developments in regenerative medicine and cell therapy and by investment in induced pluripotent stem cell lines, organoid models, and gene-edited therapeutics, and it imposes the most stringent viability requirements since the harvested cells are the therapeutic product itself. Other applications, including cancer research and vaccine development, complete the structure. The biopharmaceutical segment is expected to retain its leading share throughout the forecast period, while stem cell research grows fastest.

Cell Harvesting Systems Market Region Analysis

Dominant Region: North America

North America accounted for a 33% share of the global cell harvesting systems market in 2025. The region is expected to account for the largest share of the global market, supported by the concentration of the biopharmaceutical and cell and gene therapy industries, the scale of biomanufacturing and clinical research investment, the strong presence of the leading bioprocessing and life-science tools companies, and a supportive regulatory environment for advanced manufacturing. The United States hosts the largest concentration of biologics and advanced therapy manufacturing capacity in the world, together with the greatest number of cell and gene therapy developers and the contract organizations that serve them, and this concentration of manufacturing and clinical activity generates the greatest regional demand for harvesting systems and consumables. Regulatory leadership reinforces the position of the region, with the United States Food and Drug Administration Advanced Manufacturing Technologies Designation Program incentivizing the deployment of self-validating automation, and with the agency's emphasis upon the reproducibility, sterility, and traceability of cell processing favoring the automated and closed harvesting systems in which the region leads. The presence of the major bioprocessing companies, high research and development intensity, strong funding for cell-based research and regenerative medicine, and frequent product launches further strengthen the region. The region is expected to retain its leading position throughout the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate in the cell harvesting systems market through 2034. The region is emerging as the principal growth engine of the market, propelled by the rapid expansion of biopharmaceutical manufacturing, the growth of cell and gene therapy development, and rising investment in biotechnology and regenerative medicine across densely populated nations including China, India, Japan, and South Korea. The region combines very large patient populations with rapidly expanding domestic biopharmaceutical industries, and the governments and private sectors of several countries are investing heavily in biomanufacturing capacity, cell therapy development, and the research infrastructure that underpins them, converting a historically smaller base into rapidly growing demand for harvesting systems and consumables. China in particular has developed a substantial cell and gene therapy sector and a growing domestic bioprocessing equipment industry, exemplified by the emergence of domestically developed automated and closed cell processing systems, and Japan and South Korea combine advanced regenerative medicine programs with sophisticated manufacturing capability. The growth of contract development and manufacturing capacity across the region, rising healthcare expenditure, expanding clinical research, and the presence of both international suppliers and capable regional manufacturers offering cost-appropriate systems all contribute. Regional growth is expected to exceed the global average across every segment.

Regional Commentary

North America

North America leads on value and adoption, holding a 33% share in 2025. The region combines the largest concentration of biologics and cell and gene therapy manufacturing with strong biomanufacturing and clinical research investment, the presence of the leading bioprocessing and life-science tools companies, and regulatory leadership through the Food and Drug Administration Advanced Manufacturing Technologies Designation Program. High research and development intensity, strong funding for cell-based research and regenerative medicine, and frequent product launches reinforce the position of the region. Near-term dynamics are shaped by the growth of cell and gene therapy, the shift to automated and closed single-use processing, and the integration of monitoring and artificial intelligence into harvest workflows.

Europe

Europe is a large and sophisticated market, supported by a substantial biopharmaceutical industry, strong academic and translational research, and the presence of several of the leading bioprocessing and cell-therapy processing companies, with Germany, the United Kingdom, France, and Switzerland the principal centers. The region hosts major bioprocessing equipment and cell-therapy technology manufacturers and a strong regenerative medicine research base, and the European regulatory framework for advanced therapy medicinal products shapes the demand for GMP-compliant closed harvesting. Substantial public and private investment in cell and gene therapy manufacturing, together with the growth of contract development and manufacturing capacity, sustains demand, while pricing and reimbursement pressure and the fragmentation of national systems temper the pace of adoption.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by the rapid expansion of biopharmaceutical manufacturing, the growth of cell and gene therapy development, and rising investment in biotechnology and regenerative medicine across China, India, Japan, and South Korea. China has developed a substantial cell and gene therapy sector and a growing domestic bioprocessing equipment industry, while Japan and South Korea combine advanced regenerative medicine programs with sophisticated manufacturing. The growth of contract manufacturing capacity, rising healthcare expenditure, expanding clinical research, and the presence of both international and cost-competitive regional suppliers drive adoption. Growth exceeds the global average across every segment.

Rest of World

The Rest of the World comprises the Middle East, Africa, and South America. Adoption is stratified. The larger Latin American markets, particularly Brazil, support growing biopharmaceutical manufacturing and clinical research, and the automated manufacturing of cell and gene therapy products has begun to expand into the region, while the Gulf states are investing in biotechnology and advanced healthcare capability, together representing steady growth. Much of Africa has limited biomanufacturing and cell processing infrastructure, so harvesting demand is concentrated in research settings and the larger regional manufacturers. Regional growth will be driven by the expansion of biopharmaceutical manufacturing, investment in cell therapy and regenerative medicine, growing clinical research, and the availability of cost-appropriate systems from international and regional suppliers.

Cell Harvesting Systems Market Competitive Landscape

The global cell harvesting systems market is classified as Moderately Concentrated. The market is led by a group of large bioprocessing and life-science tools companies that supply integrated harvesting systems, single-use consumables, and filtration alongside their broader upstream and downstream bioprocessing portfolios, with a top tier of suppliers holding a substantial share of global revenue, complemented by cell-therapy processing specialists and by research-scale harvesting device manufacturers. Competition centers upon the breadth and integration of the bioprocessing portfolio, the performance of automated and closed systems, the depth of the single-use consumables franchise, regulatory support for GMP cell processing, and increasingly upon automation, connectivity, and data. The competitive landscape is evaluated across the following dimensions:

  • Market concentration: Moderately concentrated, with a top tier of large bioprocessing suppliers holding a substantial share of global revenue alongside cell-therapy processing specialists and numerous research-scale device manufacturers, and with the scale and integration advantages of the leaders constituting a barrier to entry.
  • Leading players: Thermo Fisher Scientific, Danaher through its Cytiva business, Sartorius, and Merck lead through integrated bioprocessing portfolios spanning harvesting systems, filtration, and single-use consumables, with Terumo BCT, Lonza, and Miltenyi Biotec strong in cell-therapy processing and STEMCELL Technologies, Corning, and Revvity contesting research-scale and specialized segments.
  • Geographic reach: The leading participants maintain global commercial, manufacturing, and technical service organizations, which matter because harvesting systems require process development, validation, and service support, while regional manufacturers, notably in Asia-Pacific, serve domestic and cost-sensitive markets with increasingly capable automated and closed systems.
  • Product portfolio strength: Competitive advantage rests upon supplying the complete bioprocessing train, spanning upstream culture, harvest and clarification, and downstream purification, together with the single-use consumables consumed throughout, since developers value an integrated and validated workflow from a single accountable supplier rather than a harvesting system in isolation.
  • Pipeline strength: Development is concentrated in automated and closed cell processing platforms, single-use centrifugation and filtration, depth filtration and tangential flow filtration integration, microfluidic and continuous harvesting, real-time monitoring, and artificial-intelligence-enabled process control.
  • Strategic partnerships: Collaboration spans integration of harvesting and cell processing systems into connected workflows, exemplified by partnerships combining cell processing platforms with fill-finish and manufacturing systems, alongside alliances between equipment suppliers and cell therapy developers and contract organizations.
  • M&A activity: Acquisition is a defining dynamic, through which the large bioprocessing companies have assembled integrated portfolios by acquiring cell-therapy processing, single-use, and filtration technologies, and through which cell and gene therapy manufacturing capability continues to be consolidated.
  • Innovation focus: Innovation is shifting toward fully automated and closed processing, single-use and waste-reducing systems, integration of harvest with upstream and downstream steps, microfluidic and continuous harvesting, dissolvable microcarriers for adherent cell harvesting systems, and artificial intelligence and real-time monitoring for yield and viability optimization.
  • Regulatory standing: Demonstrated GMP compliance, support for advanced manufacturing designations, and the validation and traceability required for clinical cell processing are decisive competitive credentials, and the regulatory emphasis upon reproducibility and sterility favors the automated and closed systems and the suppliers able to support them.

Cell Harvesting Systems Market Recent Developmental Activities

In March 2026, Thermo Fisher Scientific expanded its Gibco Cell Therapy Systems portfolio with enhanced automated cell processing solutions designed to support scalable manufacturing of cell and gene therapies, improving workflow consistency and reducing manual handling. Strategic significance: deepening an integrated cell therapy processing portfolio reinforced the strategy of supplying the complete workflow, in which harvesting is one connected step, and it addressed the manual-handling and consistency limitations that automation is adopted to resolve.

Cell Harvesting Systems Market Segmentation

Cell Harvesting Systems Market Assessment by Type

  • Manual Cell Harvesters
  • Automated Cell Harvesters

Cell Harvesting Systems Market Assessment by Application

  • Biopharmaceutical
  • Stem Cell Research
  • Other Applications

Cell Harvesting Systems Market Assessment by End-User

  • Biotechnology and Biopharmaceutical Companies
  • Research Institutes
  • Other End Users

Cell Harvesting Systems Market Assessment by Geography

  • North America
  • United States Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Canada Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Mexico Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Europe
  • France Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Germany Cell Harvesting Systems Market Size in USD million (2023-2034)
  • United Kingdom Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Italy Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Spain Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Rest of Europe Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Asia-Pacific
  • China Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Japan Cell Harvesting Systems Market Size in USD million (2023-2034)
  • India Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Australia Cell Harvesting Systems Market Size in USD million (2023-2034)
  • South Korea Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Rest of the World
  • Middle East Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Africa Cell Harvesting Systems Market Size in USD million (2023-2034)
  • South America Cell Harvesting Systems Market Size in USD million (2023-2034)

Frequently Asked Questions:

Q1. At what rate is the cell harvesting systems market expected to grow?

The global cell harvesting systems market is projected to grow at a compound annual growth rate of 10.95% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the cell harvesting systems market?

The global cell harvesting systems market was valued at USD 3.59 billion in 2025 and is projected to reach USD 9.14 billion by 2034.

Q3. Which region dominates the cell harvesting systems market?

North America dominated the cell harvesting systems market with a 33% share in 2025 on a modeled basis, supported by the concentration of the biopharmaceutical and cell and gene therapy industries, the scale of biomanufacturing and clinical research investment, the presence of the leading bioprocessing and life-science tools companies, and regulatory leadership through the Food and Drug Administration Advanced Manufacturing Technologies Designation Program. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by the rapid expansion of biopharmaceutical manufacturing and cell and gene therapy development across China, India, Japan, and South Korea.

Q4. What are the key factors driving growth in the cell harvesting systems market?

The principal drivers are the continued scale-up of biologics manufacturing, since harvesting is essential to producing vaccines, recombinant proteins, and therapeutic antibodies; the rapid expansion of cell and gene therapy and regenerative medicine, including chimeric antigen receptor T-cell and stem cell therapy, which require viable cells harvested under GMP conditions; the shift toward automated and closed single-use processing that reduces contamination and labor while improving yield and reproducibility; growing demand for personalized medicine amid rising chronic and autoimmune disease; the adoption of single-use and filtration technologies; regulatory support for advanced manufacturing; and the integration of monitoring, artificial intelligence, and microfluidics.

Q5. Who are the major players in the cell harvesting systems market?

The market is moderately concentrated and led by Thermo Fisher Scientific Inc., Danaher Corporation through its Cytiva business, Sartorius AG, and Merck KGaA, which supply integrated bioprocessing portfolios spanning harvesting, filtration, and single-use consumables. Additional participants include Terumo BCT (Terumo Corporation), Lonza Group AG, Miltenyi Biotec, STEMCELL Technologies Inc., Corning Incorporated, and Revvity Inc., alongside Bio-Rad Laboratories, Bertin Technologies, Brandel, Arthrex, AVITA Medical, Teleflex, Fresenius Kabi, Ori Biotech, ThermoGenesis Holdings, and Esco Micro.

Table of Contents

1. Cell Harvesting Systems Market Introduction

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Market Overview at a Glance

2. Cell Harvesting Systems Market Executive Summary

  • 2.1. Key Highlights and Market Snapshot

3. Cell Harvesting Systems Market Key Factors Analysis

  • 3.1. Market Drivers
    • 3.1.1. Scale-Up of Biologics Manufacturing
    • 3.1.2. Expansion of Cell and Gene Therapy and Regenerative Medicine
    • 3.1.3. Shift Toward Automation and Closed Processing
    • 3.1.4. Adoption of Single-Use and Filtration Technologies
  • 3.2. Market Restraints
    • 3.2.1. High Capital Cost of Automated Systems
    • 3.2.2. Technical Complexity and Integration Challenges
    • 3.2.3. Preserving Cell Viability and Regulatory Complexity
  • 3.3. Market Opportunities
    • 3.3.1. Automated and Closed Cell Therapy Processing
    • 3.3.2. Microfluidics, Monitoring, and Emerging Markets

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1. The United States
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. China

6. Cell Harvesting Systems Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Cell Harvesting Systems Market Assessment

  • 7.1. By Type
    • 7.1.1. Manual Cell Harvesters
    • 7.1.2. Automated Cell Harvesters
  • 7.2. By Application
    • 7.2.1. Biopharmaceutical
    • 7.2.2. Stem Cell Research
    • 7.2.3. Other Applications
  • 7.3. By End-User
    • 7.3.1. Biotechnology and Biopharmaceutical Companies
    • 7.3.2. Research Institutes
    • 7.3.3. Other End Users
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.1.2. Canada Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.1.3. Mexico Cell Harvesting Systems Market Size in USD million (2023-2034)
    • 7.4.2. Europe
      • 7.4.2.1. France Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.2.2. Germany Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.2.3. United Kingdom Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.2.4. Italy Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.2.5. Spain Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.2.6. Rest of Europe Cell Harvesting Systems Market Size in USD million (2023-2034)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.3.2. Japan Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.3.3. India Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.3.4. Australia Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.3.5. South Korea Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.3.6. Rest of Asia-Pacific Cell Harvesting Systems Market Size in USD million (2023-2034)
    • 7.4.4. Rest of the World
      • 7.4.4.1. Middle East Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.4.2. Africa Cell Harvesting Systems Market Size in USD million (2023-2034)
      • 7.4.4.3. South America Cell Harvesting Systems Market Size in USD million (2023-2034)

8. Cell Harvesting Systems Market Competitive Landscape

  • 8.1. Competitive Analysis
  • 8.2. Company Share Analysis (Premium Offering)

9. Cell Harvesting Systems Market Startup Funding and Investment Trends

10. Cell Harvesting Systems Market Company and Product Profiles

  • 10.1. Thermo Fisher Scientific Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Financial Overview
    • 10.1.4. Product Listing
    • 10.1.5. Strategic Initiatives / Entropy
  • 10.2. Danaher Corporation (Cytiva)
    • 10.2.1. Company Overview
    • 10.2.2. Company Snapshot
    • 10.2.3. Financial Overview
    • 10.2.4. Product Listing
    • 10.2.5. Strategic Initiatives / Entropy
  • 10.3. Sartorius AG
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Financial Overview
    • 10.3.4. Product Listing
    • 10.3.5. Strategic Initiatives / Entropy
  • 10.4. Merck KGaA
    • 10.4.1. Company Overview
    • 10.4.2. Company Snapshot
    • 10.4.3. Financial Overview
    • 10.4.4. Product Listing
    • 10.4.5. Strategic Initiatives / Entropy
  • 10.5. Terumo BCT (Terumo Corporation)
    • 10.5.1. Company Overview
    • 10.5.2. Company Snapshot
    • 10.5.3. Financial Overview
    • 10.5.4. Product Listing
    • 10.5.5. Strategic Initiatives / Entropy
  • 10.6. Lonza Group AG
    • 10.6.1. Company Overview
    • 10.6.2. Company Snapshot
    • 10.6.3. Financial Overview
    • 10.6.4. Product Listing
    • 10.6.5. Strategic Initiatives / Entropy
  • 10.7. Miltenyi Biotec B.V. & Co. KG
    • 10.7.1. Company Overview
    • 10.7.2. Company Snapshot
    • 10.7.3. Financial Overview
    • 10.7.4. Product Listing
    • 10.7.5. Strategic Initiatives / Entropy
  • 10.8. STEMCELL Technologies Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Company Snapshot
    • 10.8.3. Financial Overview
    • 10.8.4. Product Listing
    • 10.8.5. Strategic Initiatives / Entropy
  • 10.9. Corning Incorporated
    • 10.9.1. Company Overview
    • 10.9.2. Company Snapshot
    • 10.9.3. Financial Overview
    • 10.9.4. Product Listing
    • 10.9.5. Strategic Initiatives / Entropy
  • 10.10. Revvity Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Company Snapshot
    • 10.10.3. Financial Overview
    • 10.10.4. Product Listing
    • 10.10.5. Strategic Initiatives / Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Global Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Table 2: Global Cell Harvesting Systems Market Size by Type in USD million (2023-2034)
  • Table 3: Global Cell Harvesting Systems Market Size by Application in USD million (2023-2034)
  • Table 4: Global Cell Harvesting Systems Market Size by End-User in USD million (2023-2034)
  • Table 5: Cell Harvesting Systems Market Size in North America in USD million (2023-2034)
  • Table 6: Cell Harvesting Systems Market Size in the United States in USD million (2023-2034)
  • Table 7: Cell Harvesting Systems Market Size in Canada in USD million (2023-2034)
  • Table 8: Cell Harvesting Systems Market Size in Mexico in USD million (2023-2034)
  • Table 9: Cell Harvesting Systems Market Size in Europe in USD million (2023-2034)
  • Table 10: Cell Harvesting Systems Market Size in France in USD million (2023-2034)
  • Table 11: Cell Harvesting Systems Market Size in Germany in USD million (2023-2034)
  • Table 12: Cell Harvesting Systems Market Size in the United Kingdom in USD million (2023-2034)
  • Table 13: Cell Harvesting Systems Market Size in Italy in USD million (2023-2034)
  • Table 14: Cell Harvesting Systems Market Size in Spain in USD million (2023-2034)
  • Table 15: Cell Harvesting Systems Market Size in the Rest of Europe in USD million (2023-2034)
  • Table 16: Cell Harvesting Systems Market Size in Asia-Pacific in USD million (2023-2034)
  • Table 17: Cell Harvesting Systems Market Size in China in USD million (2023-2034)
  • Table 18: Cell Harvesting Systems Market Size in Japan in USD million (2023-2034)
  • Table 19: Cell Harvesting Systems Market Size in India in USD million (2023-2034)
  • Table 20: Cell Harvesting Systems Market Size in Australia in USD million (2023-2034)
  • Table 21: Cell Harvesting Systems Market Size in South Korea in USD million (2023-2034)
  • Table 22: Cell Harvesting Systems Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Table 23: Cell Harvesting Systems Market Size in the Rest of the World in USD million (2023-2034)
  • Table 24: Cell Harvesting Systems Market Size in the Middle East in USD million (2023-2034)
  • Table 25: Cell Harvesting Systems Market Size in Africa in USD million (2023-2034)
  • Table 26: Cell Harvesting Systems Market Size in South America in USD million (2023-2034)
  • Table 27: Cell Harvesting Systems Market Competitive Landscape
  • Table 28: Cell Harvesting Systems Market Startup Funding and Investment Trends

List of Figures

  • Figure 1: Cell Harvesting Systems Market Drivers
  • Figure 2: Cell Harvesting Systems Market Restraints
  • Figure 3: Cell Harvesting Systems Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis of the Cell Harvesting Systems Market (the United States)
  • Figure 6: Regulatory Analysis of the Cell Harvesting Systems Market (Europe)
  • Figure 7: Regulatory Analysis of the Cell Harvesting Systems Market (Japan)
  • Figure 8: Regulatory Analysis of the Cell Harvesting Systems Market (China)
  • Figure 9: Porter's Five Forces Analysis of the Cell Harvesting Systems Market
  • Figure 10: Competitive Analysis of the Cell Harvesting Systems Market
  • Figure 11: Global Cell Harvesting Systems Market Size in USD million (2023-2034)
  • Figure 12: Global Cell Harvesting Systems Market Size by Type in USD million (2023-2034)
  • Figure 13: Global Cell Harvesting Systems Market Size by Application in USD million (2023-2034)
  • Figure 14: Global Cell Harvesting Systems Market Size by End-User in USD million (2023-2034)
  • Figure 15: Cell Harvesting Systems Market Size in North America in USD million (2023-2034)
  • Figure 16: Cell Harvesting Systems Market Size in the United States in USD million (2023-2034)
  • Figure 17: Cell Harvesting Systems Market Size in Canada in USD million (2023-2034)
  • Figure 18: Cell Harvesting Systems Market Size in Mexico in USD million (2023-2034)
  • Figure 19: Cell Harvesting Systems Market Size in Europe in USD million (2023-2034)
  • Figure 20: Cell Harvesting Systems Market Size in France in USD million (2023-2034)
  • Figure 21: Cell Harvesting Systems Market Size in Germany in USD million (2023-2034)
  • Figure 22: Cell Harvesting Systems Market Size in the United Kingdom in USD million (2023-2034)
  • Figure 23: Cell Harvesting Systems Market Size in Italy in USD million (2023-2034)
  • Figure 24: Cell Harvesting Systems Market Size in Spain in USD million (2023-2034)
  • Figure 25: Cell Harvesting Systems Market Size in the Rest of Europe in USD million (2023-2034)
  • Figure 26: Cell Harvesting Systems Market Size in Asia-Pacific in USD million (2023-2034)
  • Figure 27: Cell Harvesting Systems Market Size in China in USD million (2023-2034)
  • Figure 28: Cell Harvesting Systems Market Size in Japan in USD million (2023-2034)
  • Figure 29: Cell Harvesting Systems Market Size in India in USD million (2023-2034)
  • Figure 30: Cell Harvesting Systems Market Size in Australia in USD million (2023-2034)
  • Figure 31: Cell Harvesting Systems Market Size in South Korea in USD million (2023-2034)
  • Figure 32: Cell Harvesting Systems Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Figure 33: Cell Harvesting Systems Market Size in the Rest of the World in USD million (2023-2034)
  • Figure 34: Cell Harvesting Systems Market Size in the Middle East in USD million (2023-2034)
  • Figure 35: Cell Harvesting Systems Market Size in Africa in USD million (2023-2034)
  • Figure 36: Cell Harvesting Systems Market Size in South America in USD million (2023-2034)
  • Figure 37: Cell Harvesting Systems Market Competitive Landscape
  • Figure 38: Cell Harvesting Systems Market Startup Funding and Investment Trends